Evaluation the effect of asafoetida in the treatment of coronavirus infectio

Phase 2

Recruiting

• Conditions: Covid-19.; Covid-19; U07.1

• Registration Number: IRCT20200413047053N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Fever
cough
Myalgia
lymphopenia
CRP positive

Exclusion Criteria

Sensitivity to asafoetida and it derivatives
Patients with hepatic disfunction
Patients with renal disfunction
Patients with respiratory disorders
Patients who take cytotoxic or corticosteroid drugs
Nursing women
pregnant women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.

Secondary Outcome Measures

Name	Time	Method
CRP level. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit.